Tarik Mahfoud

Mohammed V University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Rachid Tanz

Mohammed V University

Hassan Errihani

Mohammed V University

Mohamed Ichou

Mohammed V University

Aziz Bazine

Sidi Mohamed Ben Abdellah University

Mohamed Réda Khmamouche

Mohammed V University

Nabil Ismaili

Université Mohammed VI des Sciences de la Santé

M. Khmamouche

Mohammed V University

Mohammed Ichou

Institut National d'Oncologie

Mohamed Mesmoudi

École Nationale de Commerce et de Gestion de Tanger

Yassir Sbitti

Mohammed V University

Cooperative Institutions

Mohammed V University

103

Hôpital Militaire Moulay Ismail

Institut National d'Oncologie

Military Hospital

Centre Hospitalier Ibn Sina

Sidi Mohamed Ben Abdellah University

National Institute of Oncology

Mohamed I University

Université Mohammed VI des Sciences de la Santé

Centre Hospitalier Universitaire Mohammed VI

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

À propos de 13 cas de compression médullaire métastatique du cancer du sein

Cancer/Radiothérapie (2010)

Tarik Mahfoud M. Khmamouche A. Debbagh R. Aassab Aziz Bazine

Regimen

10.1016/j.canrad.2010.07.462

Cite

Citations (1)

Triple malignancy in a single patient including a squamous cell carcinoma of the cervix, a colloid adenocarcinoma of the colon and a lung adenocarcinoma: A case report and literature review

International Journal of Surgery Case Reports (2017)

Tarik Mahfoud Rachid Tanz Réda M. Khmamouche Massine El Hammoumi Mohamed Allaoui

The association of two cancers in the same patient is unusual but has been widely reported in the literature, while triple malignancy in the same patient is exceptional. Indeed, only very rare cases have been described. A 70-year-old woman treated in our institute in 2006 for a tumor of the cervix. She underwent extrafascial hysterectomy. Pathology revealed a well differentiated squamous cell carcinoma of the cervix (pT1N0M0). No external pelvic radiation or brachytherapy were done. The patient remained in good control until 2013 when she presented a tumor of the ascending colon. A right hemicolectomy was made. Pathology confirmed a colloid adenocarcinoma (pT3N0M0). No adjuvant chemotherapy was given. Three years later, a Computed tomography scan of the chest revealed a nodule of the lower lobe of the left lung. Biopsy was made. Histology with immunochemistry revealed the diagnosis of lung adenocarcinoma. Positron emission tomography scan showed abnormal fluorodeoxyglucose uptake in the lung nodule with no anomaly in mediastinal nodes and no metastasis. A left lower lobectomy was performed with lymph node dissection. Pathology confirmed the diagnosis of 2.5 cm lung adenocarcinoma without node invasion (pT1N0M0). No chemotherapy was given. After 14 months, the patient remained in good control. Triple malignancy in a single patient is exceptional. The management depend on stages. Surgery is the standard of care in localized cancers.

10.1016/j.ijscr.2017.11.013

Cite

Citations (2)

Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes

Journal of Gastrointestinal Cancer (2011)

Tarik Mahfoud Rachid Tanz Mohamed Mesmoudi Mohamed Réda Khmamouche Aziz Bazine

Group B

10.1007/s12029-010-9245-x

Cite

Citations (4)

Oral chemotherapy in cancers: what about adherence?

Hematology/Oncology and Stem Cell Therapy (2012)

Rachid Tanz Tarik Mahfoud Adil Debbagh Mohammed Reda Khmamouch Aziz Bazine

Oral Cancers

10.5144/1658-3876.2012.170

Cite

Citations (0)

Primary Non-Hodgkin’s Lymphoma of the Colon: A Case Report and Literature Review

Journal of Gastrointestinal Cancer (2012)

Tarik Mahfoud Rachid Tanz Mohamed Réda Khmamouche Asmâa Regragui Mohamed Ichou

10.1007/s12029-012-9406-1

Cite

Citations (2)

Low dose weekly Irinotecan plus Bevacizumab as first line chemotherapy for metastatic colorectal cancer with poor Performance Status ECOG 3 and 4

International journal of scientific research (2018)

Rachid Tanz Tarik Mahfoud Mohamed Reda khmamouch ilyas el alami choukri el mhadi

Source

Cite

Citations (0)

Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages

Hematology/Oncology and Stem Cell Therapy (2012)

Rachid Tanz Tarik Mahfoud Aziz Bazine Rachid Aassab Nourredine Benjaafar

BACKGROUND AND OBJECTIVES: Endometrial stromal sarcomas (ESS) are rare uterine neoplasms. Surgery remains the cornerstone of treatment for early stages and consists of an abdominal hysterectomy with bilateral salpingo-oopherectomy. Despite appropriate surgical treatment, relapse rates are high (18% to 45%) and the value of adjuvant therapies is not clear. We evaluated prognostic factors and the impact of adjuvant treatment on localized ESS (stages I and II). DESIGN AND SETTING: Retrospective, case-control study conducted at the National institute of oncology in Rabat, Morocco over 10 years from 2000 to 2009. PATIENTS AND METHODS: Twenty-one cases of localized ESS were included in the analysis. RESULTS: standard surgery was performed in 71.4% of our patients. Myometrial invasion was noted in 57.1% of cases. mitotic activity was considered high in five patients. Adjuvant treatment was given to 52.3% of patients: endocrine therapy in five patients and radiotherapy in six. Survival was significantly longer in the group of patients who underwent standard surgical treatment ( P =.0007), in the absence of deep myometrial invasion ( P =.0248) in cases with a low mitotic index ( P <.0001) and in patients who received adjuvant therapy (hormone or radiotherapy) ( P =.0048). In a multivariate analysis independent risk factors for monitoring were inadequate surgical treatment and absence of adjuvant treatment. CONCLUSIONS: Myometrial invasion and mitotic index appear to be important prognostic factors. The reference surgery is hysterectomy with bilateral salpingo-oopherectomy. Lymph node dissection does not appear to provide a benefit. Finally adjuvant treatment may carry a significant survival benefit.

Endometrial stromal sarcoma

Adjuvant Therapy

10.5144/1658-3876.2012.31

Cite

Citations (8)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?

Oncology Reviews (2011)

Nabil Ismaili Sanaa Elmajjaoui Youssef Bensouda Rhizlane Belbaraka Halima Abahssain

Bladder cancer is the fourth most common cancer for men and the eighth most common cancer for women. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting the treatment is based on cisplatin chemotherapy regimens type MVAC, MVAC-HD or gemcitabine plus cisplatin. The standard treatment of muscle invasive operable bladder cancer (T2–T4) used widely was radical cystectomy with pelvic lymph nodes dissection; the anatomical extent of pelvic lymphadenectomy has not accurately been defined so far. However, in the last decade, the treatment of tumors was improved by the introduction of chemotherapy as part of the management of the disease. Neoadjuvant chemotherapy should be considered at first, as standard treatment of choice, before local treatment for patients with good performance status (0–1) and good renal function–glomerular filtration rate (GFR) >60 mL/min. For patients treated with primary surgery, adjuvant chemotherapy is a valuable option in the case of lymph nodes involvement. This brief review would provide the evidence of the role of neoadjuvant chemotherapy in the management of operable muscle invasive (T2–T4) bladder cancer.

Lymphadenectomy

10.4081/oncol.2011.185

Cite

Citations (0)

Cancer du sein métastatiques : intérêt du CA 15-3

Cancer/Radiothérapie (2010)

Tarik Mahfoud A. Debbagh M. Khmamouche Yassine Moussaid R. Aassab

INT

10.1016/j.canrad.2010.07.595

Cite

Citations (0)

Toxicité inhabituelle du bevacizumab (Avastin®) : hyperlipémie ?

Cancéro digest (2011)

Mohamed Réda Khmamouche Yassir Sbitti Tarik Mahfoud Yassine Moussaid Adil Debbagh

Le bevacizumab (Avastin ® ) est un anticorps monoclonal exercant une activite antiangiogenique. Son utilisation apporte un gain en survie dans plusieurs localisations tumorales en phase metastatique dont le cancer du sein, le cancer colorectal, le cancer du rein et le cancer bronchique non a petites cellules. Ce traitement est pourvoyeur de toxicites specifiques comme l'hypertension arterielle, la proteinurie, les perforations digestives ou les evenements thromboemboliques arteriels. Nous rapporterons une serie de 7 cas d'hyperlipemies apparues (5 cas) ou s'etant aggravees (2 cas) lors d'un traitement par bevacizumab. Tous nos malades ont evolue favorablement par les mesures hygieno-dietetiques, associees ou non a un traitement medical par statines.

10.4267/2042/38767

Cite

Citations (0)